Navigation Links
CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Date:4/28/2009

in man in a similar manner as seen to isolated murine and human dendritic cells ex vivo and in vivo in the mouse. Dendritic cells direct the subsequent immune response to a vaccine by presenting the vaccine's antigen(s) to the appropriate T lymphocyte and then deliver specific cytokine proteins to the T cell to determine the immune response outcome to the specific vaccine.

Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models. In CEL-SCI's L.E.A.P.S. swine flu vaccine the TCBLs will be coupled to two different and known highly conserved peptide protective epitopes from two different essential proteins common to all influenza A virus strains.

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the dendritic and T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to an Immune / T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificit
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. Novel Technology Breaks Through Cancer Pain
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Advanced Cell Technology Announces Proposed Financing
6. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
10. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
11. China Technology Announces New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada.  Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...
(Date:3/3/2015)... , March 2, 2015  Phillip Sharp, Institute ... member of the Department of Biology and the Koch Institute ... Medal at Heritage Day , May 14, at ... of the Othmer Gold Medal since it was first ... "In 1977 Phil Sharp gave the scientific ...
(Date:3/2/2015)... York, NY (PRWEB) March 02, 2015 ... Testing Services industry has experienced robust growth. The ... consumer products, industrial materials, energy resources and other goods, ... and rising government regulation. As a result, IBISWorld forecasts ... of 2.8% to reach $946.8 million over the five-year ...
(Date:3/2/2015)... 2, 2015 VLP Therapeutics, LLC. ("VLP"), ... focusing on the research and development of therapeutic ... based upon a novel and proprietary vaccine technology, ... Impact Grant Award from the Montgomery County Department ... MCDED, is awarded to life sciences companies in ...
Breaking Biology Technology:BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2
... Brings Expertise in Single Molecule Fluorescence and ... Nanoscale Measurement ... a developer,of breakthrough nanoscale whole genome imaging platforms for ... of noted biophysicist Paul R. Selvin, Ph.D., to its,Scientific ...
... needs of the medical community; builds on proven ... efficacy and safety of TRELSTAR(R) ... WPI ), a leading specialty pharmaceutical,company, announced today that ... delivery system for TRELSTAR(R) (triptorelin,pamoate for injectable suspension), a palliative ...
... April 30 Computer Sciences,Corporation (NYSE: CSC ... chief,medical officer and vice president of its North ... 10 in Modern Physician and Modern,Healthcare magazines, annual ... in April. Readers from both magazines nominated 7,300,physician ...
Cached Biology Technology:BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board 2BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board 3FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA 2FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA 3FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA 4FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA 5CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... December 11, 2012 A new study published in ... with reductions in the level of cellular adhesion molecules ... immune function. Cell adhesion molecules are the glue ... adhesion molecules would be expected to compromise processes at ...
... Medicine and AstraZeneca, a global biopharmaceutical company, today announced ... to assess the effectiveness of AZD5847, a new test ... HIV co-infection. The study is sponsored by the ... of the U.S. National Institutes of Health. It is ...
... Public opinion on environmental issues such as climate change, ... partisan lines. But new research suggests that environmental messages ... stewardship in terms of fending off threats to the ... may help to narrow the partisan gap. A ...
Cached Biology News:Does the brain become unglued in autism? 2New tuberculosis drug trial begins in South Africa 2Messages that speak to conservatives' morals narrow partisan gap on environment 2Messages that speak to conservatives' morals narrow partisan gap on environment 3
... Synergistic enzyme mix (Thermoprime Plus DNA ... At least four times higher fidelity than ... of standard Taq DNA polymerase, Amplifies DNA ... PCR, long PCR, PCR for cloning and ...
... Methylation-specific PCR (MSP) is a new ... gene methylation utilizing small amounts of ... initial bisulfite reaction to modify the ... specific primers designed to distinguish methylated ...
... m7G(5')ppp(5')G (Cap Analog) is used for the ... in vitro transcription reactions. Substitution of cap ... GTP in an in vitro transcription reaction ... structure into a large fraction of the ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. iEMS Incubator/Shaker ... one-cabinet model, allowing the capacity ...
Biology Products: